novo nordisk glp 1 justifies reasoning behind failed GLP-1 Alzheimer's trials FDA panel supports cardiovascular indication
Description
This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access 189,00 per year only 15,75 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
Schnell O., Weng J., Sheu W
Ranking of treatments by P-score value for all outcomes
Studies show that approximately two-thirds of weight lost on GLP-1 medications is regained within a year of stopping
